Life Science News

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX: VMD.TO), a home medical equipment supplier and the nation's largest independent provider of ventilation that provides post-acute respiratory care services, today reported its financial results for the three months and year ended December 31, 2021.

Operational highlights (all dollar amounts are USD):

  • Net revenues attributable to the Company's core business for the quarter ended December 31, 2021 were $29.0 million, a new Company record and an increase of 11% over the quarter ended December 31, 2020. Net revenues attributable to the Company's core business for the quarter ended December 31, 2021 were up approximately 4% over the quarter ended September 30, 2021. Total net revenues for the current quarter were $32.0 million and included $3.0 million of net revenues for contact and vaccine tracing services and product sales related to the COVID-19 pandemic. Net revenues for the year ended December 31, 2021 were $117.1 million for the Company, including $8.6 million of COVID-19 related sales and services.

  • Net income for the quarter ended December 31, 2021 totaled approximately $4.1 million, compared to $5.1 million for the quarter ended December 31, 2020. Net income for the year ended December 31, 2021 totaled approximately $9.1 million, compared to $31.5 million for the year ended December 31, 2020. In the prior year, net income included an income tax benefit of $5.2 million and $34.4 million of COVID-19 response sales and services during the height of the COVID-19 pandemic.

  • Adjusted EBITDA for the quarter ended December 31, 2021 totaled approximately $9.5 million. Adjusted EBITDA for the year ended December 31, 2021 totaled approximately $29.3 million. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.

  • The Company had a cash balance of $28.4 million at December 31, 2021 ($31.0 million at December 31, 2020) and an overall working capital balance of $29.5 million ($24.2 million at December 31, 2020). Total long-term debt as of December 31, 2021 was $4.3 million.

  • The Company expects to generate net revenues attributable to its core business of approximately $29.2 million to $30.2 million during the first quarter of 2022. In addition to its core business, the Company is continuing to pursue additional revenues related to the COVID-19 pandemic and estimates first quarter 2022 revenues of approximately $1.4 million to $1.8 million related to the COVID-19 pandemic. Total revenues for the first quarter of 2022 are estimated to be approximately $30.6 million to $32.0 million.

"We believe organic growth trends are emerging during the periods following COVID surges," said Casey Hoyt, Viemed's CEO. "Following the Delta variant surge during the third quarter, our sales and clinical teams returned to the field in the fourth quarter eager to serve the strong demand in the market. As a result, we finished the quarter with record setting core revenues and active patient count. As we look forward to the upcoming year, we are excited to meet this demand with the innovative service offerings, which we invested in during the pandemic."

Conference Call Details

The Company will host a conference call to discuss fourth quarter results on Tuesday, March 8, 2022 at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

877-407-6176 (US Toll-Free)
201-689-8451 (International)

Live Audio Webcast:

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.


Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at

For further information, please contact:

Glen Akselrod
Bristol Capital

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the first quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company's novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and ventilators that we distribute and sell; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at, including the Company's most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada available at . Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

(Expressed in thousands of U.S. Dollars, except share amounts)

December 31, 2021
December 31, 2020
Current assets
Cash and cash equivalents $ 28,408 $ 30,981
Accounts receivable, net of allowance for doubtful accounts of $7,031 and $9,013 at December 31, 2021 and December 31, 2020, respectively 12,823 12,373
Inventory, net of inventory reserve of $1,418 and $1,353 at December 31, 2021 and December 31, 2020, respectively 2,457 2,310
Income tax receivable 1,893
Prepaid expenses and other assets 1,729 1,511
Total current assets $ 47,310 $ 47,175
Long-term assets
Property and equipment, net 62,846 55,056
Equity investments 2,157 733
Deferred tax asset 4,787 8,733
Other long-term assets 862 863
Total long-term assets 70,652 65,385
TOTAL ASSETS $ 117,962 $ 112,560
Current liabilities
Trade payables $ 3,239 $ 2,096
Deferred revenue 3,753 3,409
Income taxes payable 340
Accrued liabilities 8,875 12,595
Current portion of lease liabilities 464 2,741
Current portion of long-term debt 1,480 1,836
Total current liabilities $ 17,811 $ 23,017
Long-term liabilities
Accrued liabilities 757 1,292
Long-term lease liabilities 268 762
Long-term debt 4,306 5,796
Total long-term liabilities $ 5,331 $ 7,850
TOTAL LIABILITIES $ 23,142 $ 30,867
Commitments and Contingencies
Common stock - No par value: unlimited authorized; 39,640,388 and 39,185,182 issued and outstanding as of December 31, 2021 and December 31, 2020, respectively 14,014 9,181
Additional paid-in capital 7,749 7,320
Accumulated other comprehensive loss (278 ) (451 )
Retained earnings 73,335 65,643

(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)

Three Months Ended
December 31,
Year Ended
December 31,
2021 2020 2021 2020
Revenue $ 31,962 $ 31,202 $ 117,062 $ 131,309
Cost of revenue 12,300 12,024 43,652 51,198
Gross profit $ 19,662 $ 19,178 $ 73,410 $ 80,111
Operating expenses
Selling, general and administrative 14,240 12,274 54,893 52,829
Research and development 612 395 2,110 1,083
Stock-based compensation 1,305 1,301 5,150 4,882
Depreciation 233 204 851 816
Loss (gain) on disposal of property and equipment 144 96 448 (2,328 )
Other expense (income) (1,537 ) (359 ) (1,622 ) (3,952 )
Income from operations $ 4,665 $ 5,267 $ 11,580 $ 26,781
Non-operating income and expenses
Income from equity method investments (459 ) (55 ) (1,241 ) (91 )
Interest expense, net of interest income 69 100 318 509
Net income before taxes 5,055 5,222 12,503 26,363
Provision (benefit) for income taxes 968 151 3,377 (5,167 )
Net income $ 4,087 $ 5,071 $ 9,126 $ 31,530
Other comprehensive income (loss)
Change in unrealized gain/loss on derivative instruments, net of tax 52 27 173 (294 )
Other comprehensive income (loss) $ 52 $ 27 $ 173 $ (294 )
Comprehensive income $ 4,139 $ 5,098 $ 9,299 $ 31,236
Net income per share
Basic $ 0.10 $ 0.13 $ 0.23 $ 0.81
Diluted $ 0.10 $ 0.12 $ 0.22 $ 0.78
Weighted average number of common shares outstanding:
Basic 39,636,606 39,161,215 39,491,117 38,743,516
Diluted 40,529,206 41,043,419 40,680,947 40,525,737

(Expressed in thousands of U.S. Dollars)

Year Ended December 31,
2021 2020
Cash flows from operating activities
Net income $ 9,126 $ 31,530
Adjustments for:
Depreciation 11,312 9,582
Change in allowance for doubtful accounts 6,895 9,116
Change in inventory reserve 65 1,353
Share-based compensation 5,150 4,882
Distributions of earnings received from equity method investments 416
Income from equity method investments (1,241 ) (91 )
Loss (gain) on disposal of property and equipment 448 (2,328 )
Deferred income tax expense (benefit) 3,884 (8,733 )
Net change in working capital
Increase in accounts receivable (7,345 ) (9,955 )
Increase in inventory (212 ) (2,303 )
Increase in prepaid expenses and other assets (226 ) (812 )
Increase in trade payables 133 213
Increase in deferred revenue 344 94
(Decrease) increase in accrued liabilities (4,022 ) 2,308
Change in income tax payable/receivable (2,233 ) 254
Net cash provided by operating activities $ 22,494 $ 35,110
Cash flows from investing activities
Purchase of property and equipment (19,743 ) (13,044 )
Investment in equity investments (599 ) (629 )
Proceeds from sale of property and equipment 596 5,258
Net cash used in investing activities $ (19,746 ) $ (8,415 )
Cash flows from financing activities
Proceeds from exercise of options 112 1,876
Principal payments on notes payable (152 ) (142 )
Principal payments on term note (1,683 ) (1,605 )
Shares redeemed to pay income tax (1,434 )
Repayments of lease liabilities (2,164 ) (9,198 )
Net cash used in financing activities $ (5,321 ) $ (9,069 )
Net (decrease) increase in cash and cash equivalents (2,573 ) 17,626
Cash and cash equivalents at beginning of year 30,981 13,355
Cash and cash equivalents at end of period $ 28,408 $ 30,981
Supplemental disclosures of cash flow information
Cash paid during the period for interest $ 351 $ 559
Cash paid during the period for income taxes, net of refunds received $ 1,768 $ 3,311
Supplemental disclosures of non-cash transactions
Net non-cash changes to finance leases balances $ 48 $ 3,002
Net non-cash changes to operating lease balances $ 712 $ 57

Non-GAAP Financial Measures

This press release refers to "Adjusted EBITDA" which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation, and stock-based compensation. Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management. The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:

Reconciliation of Net Income to Non-GAAP Adjusted EBITDA
(Expressed in thousands of U.S. Dollars)

For the quarter ended December 31,
September 30,
June 30,
March 31,
December 31,
September 30,
June 30,
March 31,
Net Income $ 4,087 $ 1,789 $ 1,566 $ 1,684 $ 5,071 $ 2,804 $ 19,412 $ 4,243
Add back:
Depreciation 3,120 2,867 2,716 2,609 2,835 2,425 2,190 2,130
Interest expense 69 75 83 91 100 116 135 158
Stock-based compensation 1,305 1,302 1,236 1,307 1,301 1,234 1,196 1,151
Income tax expense (benefit) 968 1,386 1,246 (223 ) 151 1,141 (6,646 ) 187
Adjusted EBITDA $ 9,549 $ 7,419 $ 6,847 $ 5,468 $ 9,458 $ 7,720 $ 16,287 $ 7,869

Year Ended
December 31, 2021
Net Income $ 9,126
Add back:
Depreciation 11,312
Interest expense 318
Stock-based compensation 5,150
Income tax expense (benefit) 3,377
Adjusted EBITDA $ 29,283

Use of Non-GAAP Financial Measures

Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. It is not a measurement of the Company's financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company's operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company's industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Key Financial and Operational Information
(Expressed in thousands of U.S. Dollars, except vent patients)

For the quarter ended December 31,
September 30,
June 30,
March 31,
December 31,
September 30,
June 30,
March 31,
Financial Information:
Revenue $ 31,962 $ 29,285 $ 27,399 $ 28,416 $ 31,202 $ 33,447 $ 42,854 $ 23,806
Gross Profit 19,662 18,381 17,625 17,742 19,178 19,453 25,927 15,553
Gross Profit % 62 % 63 % 64 % 62 % 61 % 58 % 61 % 65 %
Net Income 4,087 1,789 1,566 1,684 5,071 2,804 19,412 4,243
Cash and Cash Equivalents (As of) 28,408 26,867 31,151 31,097 30,981 32,396 29,707 8,409
Total Assets (As of) 117,962 115,486 111,014 113,001 112,560 113,969 112,178 86,801
Adjusted EBITDA (1) 9,549 7,419 6,847 5,468 9,458 7,720 16,287 7,869
Operational Information:
Vent Patients (2) 8,405 8,200 8,103 7,733 7,892 7,788 7,705 7,965

(1) Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.

(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Bloom Health Partners CEO Andrew Morton

Bloom Health Partners CEO Andrew Morton: We're Executing the Plan That We Promised Investors

Bloom Health Partners CEO Andrew Morton: We're Executing The Plan That We Promised

Keep reading...Show less

Medtronic Board appoints Lidia Fonseca as a new director

Medtronic plc (NYSE: MDT) today announced that its Board of Directors appointed Lidia Fonseca Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022 . Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board.

"We are thrilled to welcome Lidia to Medtronic's Board of Directors," said Geoff Martha , Medtronic chairman and chief executive officer. "She has an impressive history of developing digital healthcare solutions that deliver powerful insights to improve patients' lives. Her extensive knowledge and expertise will provide the Board with an important dimension and a tremendously valuable perspective as we drive toward our bold ambition to become the global leader in healthcare technology."

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company") today announced the results of its 2022 annual meeting of shareholders and certain other updates with respect to the Company's Board of Directors (the "Board").

Annual Meeting Results

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Danaher Schedules Second Quarter 2022 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2022 on Thursday, July 21, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, , under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Applied UV

Applied UV Declares Monthly Preferred Stock Dividend

Applied UV, Inc. (NasdaqCM: AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UV's 10.5% Series A Cumulative Perpetual Preferred Stock.

Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (Nasdaq: AUVIP) shall receive a cash dividend equal to $0.21875 per share.

Keep reading...Show less

Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company") today announced the Company is providing a presentation on its business during the Company's Annual Meeting of Shareholders on June 21, 2022 . The presentation will be available on the Investor Relations section of the Bausch Health website. The Company has filed a Form 8-K this morning, annexing this presentation.

About Bausch Health

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News